Phase II Study of Eribulin Mesylate, Trastuzumab, and Pertuzumab in Women With Metastatic, Unresectable Locally Advanced, or Locally Recurrent HER2-Positive Breast Cancer
In this study, the investigators are testing the effectiveness of the combination of eribulin, pertuzumab and trastuzumab to learn whether this combination of drugs works in treating advanced HER2-positive breast cancer that had received at least one prior treatment previously. At this point, the standard treatment for HER2-positive cancer that has progressed (grown) after a first treatment is chemotherapy combined with therapies that target the HER2 protein (e.g., trastuzumab or lapatinib).
All of the medications that are being tested in this study are approved by the Food and Drug administration (FDA) for the treatment of metastatic breast cancer. However, the combination of these three medications in participants has not yet been tested. Eribulin is a chemotherapy agent that is approved for the treatment of metastatic breast cancer for women who have previously received at least two prior chemotherapeutic regimens for the treatment of their metastatic disease. Pertuzumab and trastuzumab are also both approved for the treatment of advanced HER2-positive breast cancer. Both agents help treat breast cancer by binding HER2 receptor. However, pertuzumab and trastuzumab bind to different parts of the HER2 receptor.
The goal of this research study is to find out if adding pertuzumab, trastuzumab and eribulin is effective in treating women with metastatic, HER2-positive breast cancer. The Investigators, will also gather more information on the side effects of these treatments
The investigators also plan to gather genetic information from participants' tumors (collected at biopsies). Cancers occur when the molecules that control normal cell growth (genes and proteins) are altered. Changes in the tumor genes and in the genes of normal cells are called "alterations." Many of these alterations can be detected by directly examining cancer cells in a tumor or circulating in blood. Several alterations that occur repeatedly in certain types of cancers have already been identified. These discoveries have led to the development of new drugs that "target" those alterations. More remain to be discovered.
Some of the alterations are found in genes. Genes are composed of DNA "letters," which contain the instructions that tell the cells in our bodies how to grow and work. Genes make proteins which actually carry out the instructions in our cells.
The investigator would like to use your DNA to look for alterations in the genes in cancer cells and blood cells using a technology called "sequencing." Gene sequencing is a way of reading the DNA to identify errors in genes that may contribute to the behavior of cells. Some changes in genes occur only in cancer cells. Others occur in normal cells as well, in the genes that may have been passed from parent to child. This research study will examine both kinds of genes.
One of the scientific goals of this research study is to perform gene sequencing (gene tests) on your cancer cells (obtained from biopsies or surgery) and normal tissues (usually blood). The results of the gene tests will be used to try to develop better ways to treat and prevent cancers. As part of this work, we may also learn things about the genes in your normal cells. However, because interpretation of these tests will require further study,the investigator will not disclose these results to participants who participate on this component of the study.
HER-2 Positive Breast Cancer
Drug: Pertuzumab, Trastuzumab and Eribulin
|Study Design:||Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
|Official Title:||A Phase II Study of Eribulin Mesylate in Combination With Trastuzumab and Pertuzumab in Women With Metastatic, Unresectable Locally Advanced, or Locally Recurrent Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer|
- Safety and tolerability of the combination regimen [ Time Frame: 2 Years ] [ Designated as safety issue: Yes ]Determine if the combination of eribulin mesylate, perutuzmab, and trastuzumab can be administered with 1.4 or 1.1 mg/m2 of eribulin mesylate
- Efficacy of treatment regimen [ Time Frame: 2 Years ] [ Designated as safety issue: No ]Evaluate the anti-tumor activity of the combination therapy by objective response rate (ORR). Objective response rate (ORR) is defined as complete response (CR) or partial response (PR) by RECIST 1.1 criteria
- Clinical benefit rate (CBR) [ Time Frame: 2 years ] [ Designated as safety issue: No ]To describe clinical benefit rate (CBR), defined as CR, PR and stable disease (SD) ≥ 6 months by RECIST 1.1 criteria.
- Progression-free survival (PFS) [ Time Frame: 2 Years ] [ Designated as safety issue: No ]defined as the time from the date of the first dose of study treatment until the date of first documentation of progressive disease (PD) or death from any cause (whichever occurs first).
- overall survival (OS) [ Time Frame: 2 Years ] [ Designated as safety issue: No ]defined as the time from the date of the first dose of study treatment until the date of death from any cause.
- Explore mechanisms of benefit and resistance of HER2-directed therapy: [ Time Frame: 2 Years ] [ Designated as safety issue: No ]
- describe the frequency of acquiring MET (Hepatocyte growth factor receptor) amplification in circulating tumor cells (CTCs) at the time of disease progression
- describe the association between whole exome sequencing and copy number findings and clinical outcomes (ORR, CBR, PFS and OS)
- Compare whole exome sequencing and copy number findings between primary and metastatic tumors [ Time Frame: 2 Years ] [ Designated as safety issue: No ]
- Compare whole exome sequencing and copy number findings between pre-treatment and resistant tumors. [ Time Frame: 2 Years ] [ Designated as safety issue: No ]
|Study Start Date:||August 2013|
|Estimated Study Completion Date:||January 2021|
|Estimated Primary Completion Date:||May 2017 (Final data collection date for primary outcome measure)|
Experimental: Pertuzumab, Trastuzumab and Eribulin
To evaluate the activity of trastuzumab and pertuzumab in combination with eribulin mesylate in women with metastatic or locally recurrent HER2-positive breast cancer that are refractory to trastuzumab-containing regimens.There will be a safety run-in prior to the start of the Phase II study. Each study treatment cycle lasts 21 days (3 weeks). The patient will receive eribulin on the first day (day 1) and on the 8th day (day 8) of the cycle. The patient will also receive trastuzumab and pertuzumab on day 1. All drugs will be given to the patient intravenously in clinic. The dose of pertuzumab and trastuzumab will be the same for everyone on study, and will be the standard approved dose for each of these medications.
Drug: Pertuzumab, Trastuzumab and Eribulin
Each study treatment cycle lasts 21 days. The patient will receive eribulin on the first day (day 1) and on the 8th day (day 8) of the cycle. The patient will also receive trastuzumab and pertuzumab on day 1. All drugs will be given to intravenously in clinic.
In the first portion of the study, we will examine which dose of eribulin is the safest when given in combination with pertuzumab and trastuzumab. For the first 6 participants enrolled onto the study, we will be look to see if the standard dose of eribulin can be administered safely with standard doses pertuzumab and trastuzumab. If this dose of eribulin is not tolerated well, we will test the three-medication combination with a lower dose of eribulin. The highest dose that will be found to be safe will be used in the next participants. The dose you receive will depend on the number of participants who have been enrolled in the study before you and how well they have tolerated their doses.
Show Detailed Description
|Contact: Rachel Freedman, MD||617) firstname.lastname@example.org|
|United States, Massachusetts|
|Beth Israel Deaconness Medical Center||Recruiting|
|Boston, Massachusetts, United States, 02215|
|Contact: Nadine Tung, MD 617-667-7081 email@example.com|
|Principal Investigator: Nadine Tung, MD|
|Dana-Farber Cancer Institute||Recruiting|
|Boston, Massachusetts, United States, 02115|
|Contact: Rachel Freedman, MD firstname.lastname@example.org|
|Principal Investigator: Rachel Freedman, MD|
|Boston, Massachusetts, United States, 02133|
|Contact: Erica Mayer, MD EMAYER@PARTNERS.ORG|
|Principal Investigator: Erica Mayer, MD, MPH|
|Massachusetts General Hospital||Not yet recruiting|
|Boston, Massachusetts, United States, 02114|
|Contact: Steven Isakoff, MD, PhD 617-726-4920 email@example.com|
|Principal Investigator: Steven Isakoff, MD, PhD|
|Principal Investigator:||Rachel Freedman, MD||Dana-Farber Cancer Institute|